

IN THI	E UNITED STATES PATENT AND TRADEMARK OFFICE
Serial No.: Filing Date: For: Docket No.	Wagle, et al. 09/766,547 Art Unit: 1614 January 19, 2001 Examiner: Unknown Thiazole, Imidazole and Oxazole Compounds and Treatments of Disorders Associated with Protein Aging. 361331-501
Commissioner for Pa Washington, DC 202	
the United States Po	t this correspondence is being deposited with sufficient postage with ostal Service as first-class mail in an envelope addressed to: Patents, Washington, D.C. 20231, on June 20, 2002. By: Peggy Ferello Peggy Ferello
	IATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56
the documents:	cants herein make available to the Patent and Trademark Office copies of
☑	listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
	listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:
	Serial No, filed;
	Serial No, filed;
	Examiner is requested to consider carefully the complete text of these tion with the examination of this application. It is believed that the



JUL 1 1 2002

TECH CENTER 1600/2900

Examiner will with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This Information Disclosure Statement is being filed:						
	within three months of the filing date of the patent application.						
	within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.						
	before the mailing date of a first Office Action on the merits.						
	after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:	Notice of Allowance under 37 CFR 1.311, and accordingly is					
	the Statement under 37 CFR 1.97(e) (see "Statement" below);					
	or						
	the Fee of \$180.00 set forth in 37 CFR 1.17(p); or						
	No fee is owed by the applicants.						
	after the mailing date of a Final Office Action under 37 CFR 1.116 or Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).						
(2)	Statement						
	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.	e					



RECEIVED

JUL 1 1 2002

(If this box is checked, do not check any further Statement boxes.) TECH CENTER 1600/2900

	or
	The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
The per	son making the statement is:
	the inventor(s) who sign(s) below:
	Signature of the Inventor(s)
	Typed or Printed Name of the Inventor(s)
	or
	a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:
	Signature of the Person(s)
	Typed or Printed Name of the Person
	Address of Person Signing
	or
	the undersigned attorney who signs on the basis of the information:
(supplied by the inventor(s).
[supplied by an individual designated in 37 CFR 1.56(c).
[in the attorney's file.
-	Signature of the Attorney



RECEIVED

JUL 1 1 2002

TECH CENTER 1600/2900

(3)	Petition						
		Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)					
(4)	Fees						
	\boxtimes	No Fee is owed by the applicants.					
		The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.					
		The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.					
(5)	Method of Payment of Fees						
		Attached is a check in the amount of \$240.00.					
		Charge Account No. 04-0480 in the amount of $$180.00$. (A duplicate of this request is attached).					
(6)	Authorization to Charge Additional Fees						
	\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.					
(7)	Instructions as to Overpayment						
	\boxtimes	Please credit Account No. 04-0480 for any overpayment.					
		Please refund Dechert Price & Rhoads in the amount of					

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Arthur E. Jackson Registration No. 34,354

DECHERT Princeton Pike Corporate Center PO Box 5218

Princeton, New Jersey 08543-5218

Fax: (609) 620-3259

Attn: Arthur E. Jackson, Esq.

(609 620-3254)

126172.1.07





Form PTO - 1449 U.S. Department of Commerce (Modified)

Patent and Trademark Office

Attorney Docket No. 361331-501

|Serial No.: 09/766,547 Applicant: Wagle, et al.

Filing Date: January 19, 2001

Group No. 1614

Information Disclosure Statement by Applicant

(use several Sheets if necessary)

U.S. PATENT DOCUMENTS

Exm Initi		Patent Number	Issue Date	Patentee	Class	Sub- Class	Filing Date If Appropriate
	A1	6,297,266 B1	10/2/01	Alig, et al.	514	370	
	A2	6,320,054 B1	11/20/01	Alig, et al.	548	196	
	А3	5,853,703	12/29/98	Cerami, et al.	424	53	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	_							
Exmr		Document Number	Publn			Sub-	Transl	ation?
Initial			Date*	Country or Patent	Class	Class	Yes	No
				Office				
					1			
					1			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication**)

Examir	ner	Date Considered	

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 2)

126171.1.07

Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.